???global.info.a_carregar???
Identificação

Identificação pessoal

Nome completo
Pedro Castelo Branco

Nomes de citação

  • Branco, Pedro
  • Pedro Castelo-Branco

Identificadores de autor

Ciência ID
E015-7F8F-5CA1
ORCID iD
0000-0002-3453-3978
Google Scholar ID
https://scholar.google.pt/citations?user=oEnd7XMAAAAJ&hl=pt-PT&oi=ao
Formação
Grau Classificação
2020
Concluído
Habilitation in biology (Título de Habilitação de Coordenação Científica)
Sorbonne Université, França
2000 - 2005
Concluído
Universidade de Oxford (Doutoramento)
Universidade do Algarve, Portugal
"Polypyrimidine Tract Binding Protein (PTB) Regulates mRNA 3' End Formation in Mammals" (TESE/DISSERTAÇÃO)
1993 - 1998
Concluído
Biologia (Licenciatura)
Universidade de Aveiro, Portugal
Percurso profissional

Ciência

2008/11 - 2014/02 Pós-doutorado (Investigação)
University of Toronto - Mississauga, Canadá
2006/02 - 2008/07 Pós-doutorado (Investigação)
Massachusetts General Hospital, Estados Unidos
1999/03 - 2000/10 Investigador (Investigação)
Universidade do Porto Instituto de Biologia Molecular e Celular, Portugal
1998/12 - 1999/03 Investigador (Investigação)
Instituto Português do Desporto e Juventude, Portugal
1997/10 - 1998/03 Investigador (Investigação)
Université de Tours, França

Docência no Ensino Superior

2014 - 2018 Professor Auxiliar (Docente Universitário)
Universidade do Algarve, Portugal

Cargos e Funções

2019/09 - Atual Presidente
Universidade do Algarve Departamento de Ciências Biomédicas e Medicina, Portugal
2014 - Atual Dirigente de laboratório, instituto, museu, centro ou observatório
Universidade do Algarve Departamento de Ciências Biomédicas e Medicina, Portugal
2015 - 2018 Conselho científico/técnico-científico ou orgão correspondente
Universidade do Algarve, Portugal
Projetos

Bolsa

Designação Financiadores
2019 - 2024 Epigenetic Marks for Human Sepsis
Investigador
Canadian Institutes of Health Research, Canadá
2018 - 2021 Decoding breast cancer evolution through mutant allele differential expression signatures
FEDER/FCT, ALG-01-0145-FEDER-3147
Investigador
2018 - 2021 Decoding breast cancer evolution through mutant allele differential expression signatures
FEDER/FCT, ALG-01-0145-FEDER-3147
N/A
2015 - 2020 Targeting the telomere maintenance pathway for cancer diagnostics and therapeutics.
Investigador
Canadian Cancer Society, Canadá
2015 - 2020 Novel implications of THOR hypermethylation in telomere maintenance and gliomagenesis.
Investigador
2018 - 2019 Xenografting of bovine ovarian tissue as a model for testing new drugs and examining angiogenesis, follicle premature depletion and dynamics
Investigador
2016 - 2018 The role of telomere maintenance in urologic maligancies.
Orientador
2015 - 2018 The diagnostic, prognostic and therapeutic role of THOR in breast cancer.
Orientador
2016 - 2017 Uncovering novel therapeutic targets that regulate the self-renewal capacity of colorectal cancer.
Orientador
2015 - 2017 Utilization of THOR hypermethylation for stratification and noninvasive detection of cancer
Investigador
2015 - 2016 McLaughlin Centre Accelerator Grants in Genomic Medicine and Health Informatics. Epigenetic Profiling in Severe Sepsis (EPSIS).
Investigador
2015 - 2016 Epigenetic Profiling in Severe Sepsis (EPSIS).
Investigador
2015 - 2016 miRNAs marcadores séricos de doença testicular ativa
Investigador
2015 - 2016 Diagnostic, prognostic and therapeutic implications of THOR – Tert Hypermethylated Oncologic Region in breast cancer.
Investigador responsável
2010 - 2015 Prediction and Prevention of glioma recurrence by targeting telomere dependent self-renewal capacity of tumor initiating cells.
Outra
2012 - 2014 O papel da leptina no microambiente e oncogenese do carcinoma da prostata.
Investigador
2011 - 2013 O efeito de terapeuticas usadas no carcinoma da prostata na subpopulação de células estaminais cancerosas prostáticas
PTDC/BIM-ONC/0377/2012
Investigador
2010 - 2013 Exhaustion of tumor initiating cells by targeting their self-renewal capacity with telomerase inhibition
Outra
2012 - 2012 hTERT methylation as a diagnostic and predictive tool for various tumors.
Outra
Produções

Publicações

Artigo em revista
  1. Binnie, Alexandra; Fernandes, Emanuel; Almeida-Lousada, Helder; de Mello, Ramon Andrade; Castelo-Branco, Pedro. "CRISPR-based strategies in infectious disease diagnosis and therapy". Infection (2021): http://dx.doi.org/10.1007/s15010-020-01554-w.
    10.1007/s15010-020-01554-w
  2. De Mello, Ramon Andrade; Neves, Nathália Moisés; Amaral, Giovanna Araújo; Lippo, Estela Gudin; Castelo-Branco, Pedro; Pozza, Daniel Humberto; Tajima, Carla Chizuru; Antoniou, Georgios. "The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer". Journal of Clinical Medicine 9 6 (2020): 1918. http://dx.doi.org/10.3390/jcm9061918.
    10.3390/jcm9061918
  3. Binnie, Alexandra; Tsang, Jennifer L. Y.; Hu, Pingzhao; Carrasqueiro, Gabriela; Castelo-Branco, Pedro; dos Santos, Claudia C.. "Epigenetics of Sepsis". Critical Care Medicine 48 5 (2020): 745-756. http://dx.doi.org/10.1097/ccm.0000000000004247.
    10.1097/ccm.0000000000004247
  4. De Mello, Ramon Andrade; Ayoub, Emili; Castelo-Branco, Pedro; De Almeida Zia, Victor Andre; Savio, Andre; Pozza, Daniel Humberto; Tadokoro, Hakaru; Teich, Nelson. "Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the U.K. Perspective.". Journal of Clinical Oncology 38 6_suppl (2020): 689-689. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.689.
    10.1200/jco.2020.38.6_suppl.689
  5. Binnie, Alexandra; Walsh, Christopher J.; Hu, Pingzhao; Dwivedi, Dhruva J.; Fox-Robichaud, Alison; Liaw, Patricia C.; Tsang, Jennifer L. Y.; et al. "Epigenetic Profiling in Severe Sepsis". Critical Care Medicine 48 2 (2020): 142-150. http://dx.doi.org/10.1097/ccm.0000000000004097.
    10.1097/ccm.0000000000004097
  6. Binnie, Alexandra; Tsang, Jennifer L. Y.; Hu, Pingzhao; Carrasqueiro, Gabriela; Castelo-Branco, Pedro; dos Santos, Claudia C.. "Epigenetics of Sepsis". Critical Care Medicine (2020): 1. http://dx.doi.org/10.1097/ccm.0000000000004247.
    10.1097/ccm.0000000000004247
  7. Pedro Castelo-Branco. "New target therapies in advanced non-small cell lung cancer: a review of the literature and future perspectives". Journal of Clinical Medicine (2020):
  8. Pedro Castelo-Branco. "A pilot study on DNA methylation profiles in critical Illness". Critical Care Medicine (2020):
  9. Pedro Castelo-Branco. "Comparative cost-effectiveness analysis of avelumab plus axitinib versus pembrolizumab plus axitinib, ipilimumab plus nivolumab, and sunitnib for advanced renal cell carcinoma in the UK perspective". Journal of Clinical Oncology 38 (2020): 689-689.
  10. Lee, Donghyun D.; Leão, Ricardo; Komosa, Martin; Gallo, Marco; Zhang, Cindy H.; Lipman, Tatiana; Remke, Marc; et al. "DNA hypermethylation within TERT promoter upregulates TERT expression in cancer". Journal of Clinical Investigation 129 1 (2019): 223-229. http://dx.doi.org/10.1172/jci121303.
    10.1172/jci121303
  11. De Mello, Ramon Andrade; Faleiro, Inês; Apolónio, Joana D; Tabori, Uri; Price, Aryeh J; Roberto, Vânia P; Castelo-Branco, Pedro. "Hot topics in epigenetic regulation of cancer self-renewal for pancreatic tumors: future trends". Future Oncology 15 7 (2019): 683-685. http://dx.doi.org/10.2217/fon-2018-0153.
    10.2217/fon-2018-0153
  12. Adashek, Jacob J; Aguiar, Pedro N; Castelo-Branco, Pedro; Lopes, Gilberto L; De Mello, Ramon Andrade. "PALOMA-3 clinical trial: is there a significant benefit in overall survival for breast cancer? Is it worth it?". (2019): http://hdl.handle.net/10400.1/12884.
    10.2217/fon-2019-0044
  13. Leão, Ricardo; Lee, Donghyun; Figueiredo, Arnaldo; Hermanns, Thomas; Wild, Peter; Komosa, Martin; Lau, Irene; et al. "Combined genetic and epigenetic alterations of the TERT promoter affect clinical and biological behavior of bladder cancer". (2019): http://hdl.handle.net/10400.1/12631.
    10.1002/ijc.31935
  14. Almeida, Bernardo; Apolónio, Joana; Binnie, Alexandra; Castelo-Branco, Pedro. "Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers". (2019): http://hdl.handle.net/10400.1/12432.
  15. da Cunha, Bianca Rodrigues; Domingos, Célia; Stefanini, Ana Carolina Buzzo; Henrique, Tiago; Polachini, Giovana Mussi; Castelo-Branco, Pedro; Tajara, Eloiza Helena. "Cellular interactions in the tumor microenvironment: the role of secretome". (2019): http://hdl.handle.net/10400.1/12812.
    10.7150/jca.21780
  16. da Cunha, Bianca Rodrigues; Domingos, Célia; Stefanini, Ana Carolina Buzzo; Henrique, Tiago; Polachini, Giovana Mussi; Castelo-Branco, Pedro; Tajara, Eloiza Helena. "Cellular Interactions in the Tumor Microenvironment: The Role of Secretome". Journal of Cancer 10 19 (2019): 4574-4587. http://dx.doi.org/10.7150/jca.21780.
    10.7150/jca.21780
  17. De Mello, Ramon Andrade; Aguiar, Pedro Nazareth; Tadokoro, Hakaru; Farias-Vieira, Tállita Meciany; Castelo-Branco, Pedro; de Lima Lopes, Gilberto; Pozza, Daniel Humberto. "MetaLanc9 as a novel biomarker for non-small cell lung cancer: promising treatments via a PGK1-activated AKT/mTOR pathway". Journal of Thoracic Disease 10 S16 (2018): S2076-S2078. http://dx.doi.org/10.21037/jtd.2018.04.122.
    10.21037/jtd.2018.04.122
  18. De Mello, Ramon Andrade; Castelo-Branco, Luis; Castelo-Branco, Pedro; Pozza, Daniel Humberto; Vermeulen, Louis; Palacio, Sofia; Salzberg, Matthew; Lockhart, A. Craig. "What Will We Expect From Novel Therapies to Esophageal and Gastric Malignancies?". American Society of Clinical Oncology Educational Book 38 (2018): 249-261. http://dx.doi.org/10.1200/edbk_198805.
    10.1200/edbk_198805
  19. Leão, Ricardo; van Agthoven, Ton; Fadaak, Kamel; Castelo-Branco, Pedro; Jewett, Michael; Sweet, Joan; E. Ahmad, Ardalan; et al. "MP37-08 SERUM MIRNA PREDICTS VIABLE DISEASE POST-CHEMOTHERAPY IN TESTICULAR NON-SEMINOMA GERM CELL TUMOR PATIENTS". Journal of Urology 199 4S (2018): http://dx.doi.org/10.1016/j.juro.2018.02.1214.
    10.1016/j.juro.2018.02.1214
  20. Gouvinhas, Cláudia; De Mello, Ramon Andrade; Oliveira, Daniela; Castro-Lopes, José Manuel; Castelo-Branco, Pedro; dos Santos, Ricardo Sales; Hespanhol, Venceslau; Pozza, Daniel Humberto. "Lung cancer: a brief review of epidemiology and screening". Future Oncology 14 6 (2018): 567-575. http://dx.doi.org/10.2217/fon-2017-0486.
    10.2217/fon-2017-0486
  21. Leão, Ricardo; Apolónio, Joana D.; Lee, Donghyun; Figueiredo, Arnaldo; Tabori, Uri; Castelo-Branco, Pedro. "Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer". (2018): http://hdl.handle.net/10400.1/10529.
    http://dx.doi.org/10.1186/s12929-018-0422-8
  22. De Mello, Ramon Andrade; Escriu, Carles; Castelo-Branco, Pedro; Cabral, Paloma Lucena; Mountzios, Giannis; Lopes, Gilberto de Lima; Madureira, Pedro. "Comparative outcome assessment of epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of advanced non-small-cell lung cancer: a network meta-analysis". Oncotarget 9 14 (2017): http://dx.doi.org/10.18632/oncotarget.23668.
    10.18632/oncotarget.23668
  23. Faleiro, Inês; Apolónio, Joana Dias; Price, Aryeh J; De Mello, Ramon Andrade; Roberto, Vânia Palma; Tabori, Uri; Castelo-Branco, Pedro. "The TERT hypermethylated oncologic region predicts recurrence and survival in pancreatic cancer". Future Oncology 13 23 (2017): 2045-2051. http://dx.doi.org/10.2217/fon-2017-0167.
    10.2217/fon-2017-0167
  24. Leão, Ricardo; Domingos, Célia; Figueiredo, Arnaldo; Hamilton, Robert; Tabori, Uri; Castelo-Branco, Pedro. "Cancer Stem Cells in Prostate Cancer: Implications for Targeted Therapy". Urologia Internationalis 99 2 (2017): 125-136. http://dx.doi.org/10.1159/000455160.
    10.1159/000455160
  25. Aguiar, Pedro N; Santoro, Ilka Lopes; Tadokoro, Hakaru; de Lima Lopes, Gilberto; Filardi, Bruno Andraus; Oliveira, Pedro; Castelo-Branco, Pedro; Mountzios, Giannis; de Mello, Ramon Andrade. "A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker". Immunotherapy 8 9 (2016): 1011-1019. http://dx.doi.org/10.2217/imt-2016-0032.
    10.2217/imt-2016-0032
  26. Castelo-Branco, Pedro; Leão, Ricardo; Lipman, Tatiana; Campbell, Brittany; Lee, Donghyun; Price, Aryeh; Zhang, Cindy; et al. "A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study". Oncotarget 7 36 (2016): http://dx.doi.org/10.18632/oncotarget.10639.
    10.18632/oncotarget.10639
  27. Aguiar, Pedro Nazareth; Muniz, Thiago Pimentel; Miranda, Raelson Rodrigues; Tadokoro, Hakaru; Forones, Nora Manoukian; Monteiro, Ines-de-Paula; Castelo-Branco, Pedro; Janjigian, Yelena Y; de Mello, Ramon Andrade. "Current advances in targeted therapies for metastatic gastric cancer: improving patient care". Future Oncology 12 6 (2016): 839-854. http://dx.doi.org/10.2217/fon.15.348.
    10.2217/fon.15.348
  28. Ernst, Aurélie; Jones, David T.W.; Maass, Kendra K.; Rode, Agata; Deeg, Katharina I.; Jebaraj, Billy Michael Chelliah; Korshunov, Andrey; et al. "Telomere dysfunction and chromothripsis". International Journal of Cancer 138 12 (2016): 2905-2914. http://dx.doi.org/10.1002/ijc.30033.
    10.1002/ijc.30033
  29. Castelo-Branco, Pedro; Leao, Ricardo; Lipman, Tatiana; Campbell, Brittany; Lee, Donghyun; Price, Aryeh; Zhang, Cindy; et al. "A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: A retrospective cohort study". (2016): http://hdl.handle.net/10400.1/9293.
    10.18632/oncotarget.10639
  30. Faleiro, Inês; Leão, Ricardo; Binnie, Alexandra; Andrade de Mello, Ramon; Maia, Ana Teresa; Castelo-Branco, Pedro. "Epigenetic therapy in urologic cancers: an update on clinical trials". (2016): http://hdl.handle.net/10400.1/9150.
    10.18632/oncotarget.14226
  31. Aguiar, Pedro Nazareth Jr.; Muniz, Thiago Pimentel; Miranda, Raelson Rodrigues; Tadokoro, Hakaru; Forones, Nora Manoukian; Monteiro, Inês-de-Paula; Castelo-Branco, Pedro; Janjigian, Yelena Y.; Mello, Ramon Andrade de. "Current advances in targeted therapies for metastatic gastric cancer: improving patient care". (2016): http://hdl.handle.net/10400.1/9768.
    10.2217/fon.15.348
  32. Mistry, Matthew; Zhukova, Nataliya; Merico, Daniele; Rakopoulos, Patricia; Krishnatry, Rahul; Shago, Mary; Stavropoulos, James; et al. "BRAF Mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma". (2015): http://hdl.handle.net/10400.1/11546.
    10.1200/JCO.2014.58.3922
  33. Mangerel, Joshua; Price, Aryeh; Castelo-Branco, Pedro; Brzezinski, Jack; Buczkowicz, Pawel; Rakopoulos, Patricia; Merino, Diana; et al. "Alternative lengthening of telomeres is enriched in, and impacts survival of TP53 mutant pediatric malignant brain tumors". Acta Neuropathologica 128 6 (2014): 853-862. http://dx.doi.org/10.1007/s00401-014-1348-1.
    10.1007/s00401-014-1348-1
  34. Pedro Castelo-Branco. "Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells.". Acta Neuropathol. (2014):
  35. Taylor, M. D.; Mack, S.; Witt, H.; Dirks, P.; Pfister, S.; Korshunov, A.; Pedro Castelo-Branco. "EPIGENOME ALTERATIONS DEFINE LETHAL CIMP POSITIVE EPENDYMOMAS OF INFANCY". Nature (2014): http://10.1038/nature13108.
    10.1093/neuonc/nou206.58
  36. Pedro Castelo-Branco. "Comprehensive genomic analysis of diffuse intrinsic pontine gliomas unravels three molecular subgroups and a novel cancer driver.". Nature Genetics, (2014):
    10.1038/ng.2936.
  37. Zhukova, Nataliya; Ramaswamy, Vijay; Remke, Marc; Martin, Dianna C.; Castelo-Branco, Pedro; Zhang, Cindy H.; Fraser, Michael; et al. "WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma". (2014): http://hdl.handle.net/10400.1/12046.
    10.1186/s40478-014-0174-y
  38. Barszczyk, Mark; Buczkowicz, Pawel; Castelo-Branco, Pedro; Mack, Stephen C.; Ramaswamy, Vijay; Mangerel, Joshua; Agnihotri, Sameer; et al. "Telomerase inhibition abolishes the tumorigenicity of pediatric ependymoma tumor-initiating cells". (2014): http://hdl.handle.net/10400.1/11219.
    10.1007/s00401-014-1327-6
  39. Pedro Castelo-Branco. "Epigenomic alterations define lethal CIMP-positive ependymomas of infancy.". Nature (2014):
  40. Pedro Castelo-Branco. "Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma.". Journal of Clinical Oncology. (2013): http://europepmc.org/abstract/med/23835706.
    10.1200/JCO.2012.48.5052
  41. Castelo-Branco, Pedro; Choufani, Sanaa; Mack, Stephen; Gallagher, Denis; Zhang, Cindy; Lipman, Tatiana; Zhukova, Nataliya; et al. "Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study". The Lancet Oncology 14 6 (2013): 534-542. http://dx.doi.org/10.1016/s1470-2045(13)70110-4.
    10.1016/s1470-2045(13)70110-4
  42. Pedro Castelo-Branco. "Methylation of the TERT promoter and risk stratification of childhood brain tumours: an integrative genomic and molecular study.". The Lancet Oncology (2013): http://europepmc.org/abstract/med/23598174.
    10.1016/S1470-2045(13)70110-4
  43. Castelo-Branco, Pedro; Tabori, Uri. "Promises and challenges of exhausting pediatric neural cancer stem cells". Pediatric Research 71 2-4 (2012): 523-528. http://dx.doi.org/10.1038/pr.2011.63.
    10.1038/pr.2011.63
  44. Pedro Castelo-Branco. "Monoallelic Expression Determines Oncogenic Progression and Outcome in Benign and Malignant Brain Tumors". Journal of Cancer Research and Oncobiology (2012):
  45. Pedro Castelo-Branco. "Monoallelic expression determines oncogenic progression and outcome in benign and malignant brain tumors.". Cancer Research (2012): http://europepmc.org/abstract/med/22144470.
    10.1158/0008-5472.CAN-11-2266
  46. Pedro Castelo-Branco. "Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma.". Nature (2012): http://europepmc.org/abstract/med/22286061.
    10.1038/nature10833
  47. Castelo-Branco, P.; Zhang, C.; Lipman, T.; Fujitani, M.; Hansford, L.; Clarke, I.; Harley, C. B.; et al. "Neural Tumor-Initiating Cells Have Distinct Telomere Maintenance and Can be Safely Targeted for Telomerase Inhibition". Clinical Cancer Research 17 1 (2011): 111-121. http://dx.doi.org/10.1158/1078-0432.ccr-10-2075.
    10.1158/1078-0432.ccr-10-2075
  48. Pedro Castelo-Branco. "Neural tumor-initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition.". Clinical Cancer Research (2011): http://europepmc.org/abstract/med/21208905.
    10.1158/1078-0432.CCR-10-2075
  49. Pedro Castelo-Branco. "Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer.". Gene Therapy (2010): http://www.ncbi.nlm.nih.gov/pubmed/20220784.
  50. Castelo-Branco, P; Passer, B J; Buhrman, J S; Antoszczyk, S; Marinelli, M; Zaupa, C; Rabkin, S D; Martuza, R L. "Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer". Gene Therapy 17 6 (2010): 805-810. http://dx.doi.org/10.1038/gt.2010.20.
    10.1038/gt.2010.20
  51. Pedro Castelo-Branco. "Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells.". Cancer Gene Therapy (2009):
  52. Passer, B J; Castelo-Branco, P; Buhrman, J S; Varghese, S; Rabkin, S D; Martuza, R L. "Oncolytic herpes simplex virus vectors and taxanes synergize to promote killing of prostate cancer cells". Cancer Gene Therapy 16 7 (2009): 551-560. http://dx.doi.org/10.1038/cgt.2009.10.
    10.1038/cgt.2009.10
  53. Liu, Ta-Chiang; Castelo-Branco, Pedro; Rabkin, Samuel D; Martuza, Robert L. "Trichostatin A and Oncolytic HSV Combination Therapy Shows Enhanced Antitumoral and Antiangiogenic Effects". Molecular Therapy 16 6 (2008): 1041-1047. http://dx.doi.org/10.1038/mt.2008.58.
    10.1038/mt.2008.58
  54. Binnie, A.. "Homologous gene sequences mediate transcription-domain formation". Journal of Cell Science 119 18 (2006): 3876-3887. http://dx.doi.org/10.1242/jcs.03050.
    10.1242/jcs.03050
  55. Castelo-Branco, P.; Furger, A.; Wollerton, M.; Smith, C.; Moreira, A.; Proudfoot, N.. "Polypyrimidine Tract Binding Protein Modulates Efficiency of Polyadenylation". Molecular and Cellular Biology 24 10 (2004): 4174-4183. http://dx.doi.org/10.1128/mcb.24.10.4174-4183.2004.
    10.1128/mcb.24.10.4174-4183.2004
  56. Pedro Castelo-Branco. "Polypyrimidine tract binding protein modulates efficiency of polyadenylation". Mol. Cell. Biol. (2004):
    10.1128/MCB.24.10.4174-4183.2004
Capítulo de livro
  1. Pedro Castelo-Branco. "Histone modifications in diseases". In Histone Modification in Therapy, 1-15. Elsevier Translation Epigenetics Series, 2020.
  2. Pedro Castelo-Branco. "Gastric Cancer". In International Manual of Oncology Practice, 303-330. 2019.
  3. Pedro Castelo-Branco. "What we will expect from novel therapies to Esophageal and Gastric malignancies". In American Society of Clinical Oncology Educational Book, 249-261. 2018.
Tese / Dissertação
  1. Ramalhete, Sara Maria Ventura. "Epigenetic biomarkers as predictors of clinical outcomes in colorectal cancer". Mestrado, 2019. http://hdl.handle.net/10400.1/13422.
  2. Fonseca, André Filipe Afonso de Sousa. "Epigenetic of colorectal cancer: a focus on microRNAs". Mestrado, 2018. http://hdl.handle.net/10400.1/12546.
  3. Pagliaro, Sarah Beatriz de Oliveira. "Cancro da próstata : efeitos da quimioterapia in vitro em células estaminais cancerígenas". Mestrado, 2013. http://hdl.handle.net/10316/35775.

Propriedade Intelectual

Patente
  1. Pedro Castelo-Branco. 2018. "Method of diagnosing cancer comprising detection of the methylation signature in the hTERT promoter.". Estados Unidos.
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2019/12 Marcadores epigenéticos: A nova era da genética molecular. Jornadas ALTBiotech
Instituto Nacional de Investigação em Agronomia e Veterinária (Santarém, Portugal)
2019/02 TERT regulation in cancer: a potential therapeutic target. Epigenetic Chemical Biology COST CM1406 Scientific Workshop
Universidade do Algarve (Faro)
2019/01 Epigenética no cancro colorectal. I Jornadas de cirurgia colorrectal do Algarve
(Portimão)
2018/12 Tumor Heterogeneity – what do we need to be aware of …1st Portuguese Symposium on Research and Innovation in Urology
CUF Hospitals (Lisboa)
2018 Clinical applications of epigenetic biomarkers in cancer diagnosis and prognosis MEDLAB Europe, 18 Conferences
(Barcelona)
2016/11 Epigenetics in cancer: From Bench to Clinic V Simpósio Ciências Biomédicas
(Faro)
2016/06 TERT: factor de prognóstico nos tumores cerebrais pediátricos 2nd MEEting do MIM
Universidade do Algarve (Faro)
2015/06 TERT Hypermethylated Oncologic Region - THOR: a new epigenetic cancer biomarker.
IPATIMUP (Porto)
2015/03 TERT Hypermethylated Oncologic Region - THOR: a new epigenetic cancer biomarker. VI Jornadas de Ciencias Biomédicas
2014/11 TERT Hypermethylated Oncological Region - THOR predicts biochemical relapse amongst prostate cancer patients 1st ASPIC International meeting
2013/06 THOR methylation provides insight into the telomere maintenance landscape of malignant gliomas
(Quebec City, Canadá)
2013/05 Methylation of a specific region in the hTERT promoter is a cancer signature which correlates with tumor grade and patient survival.
(Florida)
2013/04 hTERT promoter methylation: a DNA based epigenetic cancer biomarker Global Biomarker Conference
(Toronto, Canadá)
2012/10 hTERT promoter methylation: An epigenetic cancer biomarker. CNC
Universidade de Coimbra
2012/10 hTERT promoter methylation: A DNA-based cancer biomarker Cancer Research Center
2012/10 From cancer stem cell therapies to the development of a brain tumor biomarker PhD program
Faculdade de Medicina de Coimbra
2012/06 A specific region in the hTERT promoter can predict malignancy and survival in patients with childhood brain tumors. . 15th International Symposium on Pediatric Neuro-Oncology
ISPNO (Toronto)
2011/04 Neural tumor initiating cells have distinct telomere maintenance and can be safely targeted for telomerase inhibition 6th International Meeting of the Portuguese Society for Stem Cells and Cell Therapies
2010/06 Selective targeting of neural tumor initiating cells by telomerase inhibition 14th International Symposium on Pediatric Neuro-Oncology
(Vienna)
2010/05 Selective targeting of neural tumor initiating cells by telomerase inhibition 7th Canadian Telomeres and Telomerase Symposium
2010/04 Selective Targeting of Pediatric Neural Stem Cells by Telomerase Inhibition CNC
Universidade de Coimbra
2010/04 Telomeres and Telomerase in Aging and Cancer.
Universidade de Aveiro
2009/01 Fighting Tumors with virus and telomerase inhibitors
Universidade do Algarve
2003/08 Polypyrimidine Tract Binding Protein modulates efficiency of polyadenylation Eukaryotic mRNA processing meeting
(Cold Spring Harbor)
2000/09 PTB, a multifunctional protein, is a component of the C2 mRNA 3´end formation machinery. XII Congresso de Bioquímica

Orientação

Título / Tema
Papel desempenhado
Curso (Tipo)
Instituição / Organização
2019 - Atual Epidemiologia molecular de biomarcadores de cancro esófago-gástrico
Coorientador
Universidade Federal de São Paulo Departamento de Medicina, Brasil
2019 - Atual Modulating receptor activation, migration and epigenetics of cancer cells using UV light.
Coorientador
Universidade do Algarve Departamento de Ciências Biomédicas e Medicina, Portugal
2018 - Atual Uncovering differential DNA methylation alterations in subtypes of Acute Myeloid Leukemia.
Orientador
2018 - Atual Epigenetics hotspots in cancer
Orientador
2017 - Atual Epigenetic biomarker development and big data analysis in Colorectal Cancer
Orientador
Universidade do Algarve Departamento de Ciências Biomédicas e Medicina, Portugal
2014 - Atual Endothelium non-codificant transcriptome in Neurofibromatosis type 1:“instructing cancer".
Coorientador
2015 - 2019 The diagnostic, prognostic and therapeutic role of THOR in breast cancer.
Orientador
Universidade do Algarve Departamento de Ciências Biomédicas e Medicina, Portugal
2015 - 2019 The role of telomere maintenance in urologic maligancies.
Orientador
2013 - 2017 Proliferación cellular y regulacíon de Telomerasa en el cáncer de mama.
Coorientador

Júri de grau académico

Tema
Tipo de participação
Nome do candidato (Tipo de grau)
Instituição / Organização
2020 Melanoma in zebrafish disregards telomere maintenance mechanisms.
Arguente principal
Joana Nabais (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017/06 Thymic stromal factors promoting T-cell leukemia Marinella Nobre Ghezzo (Doutoramento)
2017/06 MicroRNA Deregulation in Prostate Cancer
Arguente principal
João António Ramalho Carvalho (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2017/06 Biophysical modulation of cell fate through chromatin remodeling.
Arguente principal
Ana Francisca Silva de Lima (Doutoramento)
Universidade Nova de Lisboa, Portugal
2017/06 The impact f non-coding alterations in glioma: hints from HOTAIR and the TERT promoter
Arguente principal
Ana Xavier Silva Magalhães (Doutoramento)
Universidade do Minho Escola de Medicina, Portugal
2016 Unravelling the genetics of neuroendocrine tumors
Arguente principal
João Pedro Rico de Oliveira Vinagre (Doutoramento)
Universidade do Porto Instituto de Ciências Biomédicas Abel Salazar, Portugal
2016 HOXA9 as a key regulator in glioma initiation, aggressiveness and response to therapy.
Arguente principal
Marta Sofia Pojo Sousa (Doutoramento)

Curso / Disciplina lecionado

Disciplina Curso (Tipo) Instituição / Organização
2014 - Atual Tumor Progression (Mestrado) Universidade do Algarve, Portugal
2014 - Atual Eukaryotic Molecular Genetics - Master´s Degree in Microbial and Molecular Biology (Mestrado) Universidade do Algarve, Portugal
2014 - Atual Oncolabs I – Master´s Degree in Oncobiology (Mestrado) Universidade do Algarve, Portugal
2014 - Atual Problem Based Learning – Medical Degree. (Mestrado integrado)
2014 - Atual Human Genetics – Biomedical Sciences Degree (Licenciatura) Universidade do Algarve, Portugal
2014 - Atual Congenital Diseases – Biomedical Sciences Degree (Licenciatura) Universidade do Algarve, Portugal
2019/06 - 2019/06 How to communicate ideas, projects and results.
2019/06 - 2019/06 Epigenetic TERT regulation in cancer: from bench to bedside
2018/05 - 2018/05 Epigenetic TERT regulation in cancer: from bench to bedside University of New South Wales, Austrália
2016/11 - 2016/11 TERT Hypermethylated Oncologic Region - THOR: a new epigenetic cancer biomarker Oxford Brookes University, Reino Unido
2016/10 - 2016/10 Epigenetics in cancer: From Bench to Clinic. Epigenética Aplicada ao Diagnóstico Laboratorial Instituto Politécnico de Lisboa Escola Superior de Tecnologia da Saúde de Lisboa, Portugal
2015/12 - 2015/12 A metilação do promotor TERT como factor de prognóstico nos tumores cerebrais pediátricos
2015/12 - 2015/12 TERT Hypermethylated Oncologic Region - THOR: a new epigenetic cancer biomarker
2006 - 2007 Teaching fellow in Biological Sciences Molecular Biology Harvard University Department of Molecular and Cellular Biology, Estados Unidos
2002 - 2003 Molecular biology laboratory techniques University of Oxford Medical Sciences Division, Reino Unido

Membro de associação

Nome da associação Tipo de participação
2016 - Atual Algarve Biomedical Center Member of the Executive Committee

Membro de comissão

Descrição da atividade
Tipo de participação
Instituição / Organização
2020 - Atual National Clinical Academic Centres Council
Membro
2020 - Atual Doctoral Program in Clinical Research
Membro
Universidade do Algarve, Portugal
2020 - Atual Advisory Committee SciELO
Membro
2018 - Atual Doctoral Program in Mechanisms of Disease and Regenerative Medicine, University of Algarve/Nova Lisbon University - Board member
Membro
2016 - Atual Algarve Biomedical Center Member of the Executive Committee
Presidente / Vice-presidente
Algarve Biomedical Center, Portugal
2015 - Atual Department of Biomedical Sciences and Medicine Scientific Council
Membro
2014 - Atual Genetic Toxicology – Master´s Degree in Oncobiology.
Coordenador
Universidade do Algarve, Portugal
2014 - Atual Elective – Medical Degree.
Coordenador
Universidade do Algarve, Portugal
2014 - Atual Epigenetics – Biomedical Sciences Degree.
Coordenador
Universidade do Algarve, Portugal
2019 - 2021 Integrated Masters in Medicine Appeal Committee
Presidente / Vice-presidente
Universidade do Algarve, Portugal
2019 - 2020 Coordinating Section of the Academic Senate
Membro
Universidade do Algarve, Portugal
2018 - 2019 Integrated Masters in Medicine Appeal Committee
Membro
Universidade do Algarve, Portugal

Tutoria

Tópico Nome do aluno
2006 - 2008 Biological Sciences .
Distinções

Prémio

2013 First Prize, Genetics & Genome Biology and Molecular Medicine Program Meeting, oral competition
University of Toronto Faculty of Medicine, Canadá
2010 The Hospital for Sick Children Genetics and Genome Biology Meeting poster competition
Hospital for Sick Children SickKids Learning Institute, Canadá
1999 Scientific Investigator’s Award
Governo da República Portuguesa, Portugal

Outra distinção

2018 Tech2Marquet Honourable Mention
Universidade do Algarve, Portugal
2003 Gustav Born Scholarship in Biomedical Sciences
2000 Praxis XXI Pre-Doctoral Scholarship
Governo da República Portuguesa, Portugal
1997 Erasmus Scholarship